PRESS ROOM

Press Releases

7 December 2022
Exact Sciences Highlights the Impact of Precision Oncology Portfolio on Breast Cancer Treatment with 10 New Data Presentations at SABCS^® 2022

Press Releases

9 December 2021
New Data Presented at SABCS 2021 Strengthen Value of Oncotype DX Breast Recurrence Score^® Test to Inform Clinical Decision-making

2 December 2021
Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX^® Test

20 May 2021
New Analysis Reinforces Cost-Effectiveness of the Oncotype DX Breast Recurrence Score^® Test in Node-Positive Early-Stage Breast Cancer

25 March 2021
New NCCN Breast Cancer Guidelines Recognise Oncotype DX Breast Recurrence Score^® as the “Preferred” and Only Multigene Test to Predict Chemotherapy Benefit in Node-positive Early-stage Breast Cancer 

Press Releases

9 December 2020
RxPONDER Study Results Demonstrate that the Oncotype DX^® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer

29 May 2020
New Data and Society Guidelines Support Value of Oncotype DX Breast Recurrence Score^® Test in Guiding Neoadjuvant Treatment Decisions for Newly Diagnosed Patients

14 May 2020
New Oncotype DX^® Real-World Evidence Shows for the First Time the Practice-Changing Impact of TAILORx Results

Press Releases

12 December 2019
New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage Breast Cancer

2 October 2019
New TAILORx Data, Published in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score Test to Guide Chemotherapy Treatment

21 June 2019
German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision for Oncotype DX Breast Recurrence Score Test

4 June 2019
Secondary Analysis of Landmark TAILORx Results, Published in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score Test to Predict Chemotherapy Benefit, Guiding Adjuvant Therapy with Even Greater Precision

25 March 2019
Evidence from UK Hospitals Supports the Value of the Oncotype DX Test in Avoiding Unnecessary Chemotherapy for Patients with Node-positive Breast Cancer

Media Coverage

20 December 2019
Gene Tests to Help Breast Cancer Patients

16 October 2019
Do I Need Chemotherapy?

3 September 2019
Genomic Testing Helps Women to Tailor Their Breast Cancer Care

31 July 2019
Scottish Government to Respond to NHS Tayside Chemo Criticism in Coming Weeks

30 April 2019
Top Doctors to Help with Cancer Review at NHS Tayside

17 April 2019
NHS Tayside Chemotherapy Treatment Probe Calls for Review of Decision Making Across Health Board

23 March 2019
5,000 Breast Cancer Sufferers Could be Spared Chemotherapy if Offered Gene Testing, Study Suggests

27 February 2019
Understanding the Patient as Well as the Disease Is the Only Way to Make the NHS More Sustainable

Press Releases

19 December 2018
NICE Expands Recommendation for the Oncotype DX Test to More Patients with Early-stage Breast Cancer

11 December, 2018
New Long-term Evidence from Large Study Reinforces Value of the Oncotype DX Breast Recurrence Score Test to Guide Adjuvant Chemotherapy Treatment, Confirming TAILORx Conclusions

22 October, 2018
New Real-world Evidence Confirms Value of the Oncotype DX Test in Clinical Practice for Patients with Early-stage Breast Cancer

3 June, 2018
Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Demonstrate the Oncotype DX Breast Recurrence Score Test Definitively Identifies the 70% of Women with Early-stage Breast Cancer Who Receive No Benefit from Chemotherapy, and the 30% of Women for Whom Chemotherapy Benefit Can be Life-saving

Media Coverage

29 December 2018
NICE Publishes Updated Guidance with Expanded Recommendation for Oncotype DX

29 July 2018
HEALTH: An Exciting Breakthrough in Breast Cancer Treatment

3 June 2018
Landmark Breast Cancer Study Spares Women from Chemotherapy

3 June 2018
Thousands of Breast Cancer Patients Could Avoid Chemo, Study Finds

3 June 2018
Breast Cancer: Test Means Fewer Women Will Need Chemotherapy

Press Releases

11 December, 2017
New Results from Large Registry with 10-year Follow Up Show Excellent Outcomes for Patients with Low Oncotype DX Breast Recurrence Score^® results treated with hormonal therapy alone

11 September 2017
Genomic Test Shows that Half of Under-40s with Early Breast Cancer Have Excellent Prognosis Despite not Having Chemotherapy Treatment

12 July 2017
Updated St. Gallen International Breast Cancer Guidelines Reinforce Important Role of Genomic Testing in Treatment of Early Breast Cancer

13 June 2017
New Data Show Important Role of Genomic Testing in Treatment of Older Breast Cancer Patients

20 March 2017
Genomic Health’s Oncotype DX Breast Cancer Test Can Significantly Improve Patient Outcomes for Node-positive Patients, International Studies Reveal

6 February 2017
NHS Adoption of Oncotype DX Test Leads to Substantial Reduction in Unnecessary Chemotherapy for UK Breast Cancer Patients

Media Coverage

6 December 2017
Deciding on Chemotherapy

1 October 2017
Breast Cancer Test: New Technique Could Spare Thousands from Chemotherapy

5 February 2017
Test Could Spare 6,000 Breast Cancer Patients from Chemotherapy by Telling Doctors the Genetic Make-up of Their Tumour and How Likely It Is to Return

Press Releases

12 December 2016
New Data Demonstrate That Oncotype DX Can Help Guide Treatment Decisions Before Breast Cancer Surgery Enabling More Personalised Care, Including Avoidance of Gull Mastectomy

10 October 2016
Large Study Shows Older Breast Cancer Patients Have Worse Outcomes

20 June 2016
Updated NICE Quality Standard Recommends Oncotype DX^® in Early-stage Breast Cancer

6 June 2016
Oncotype DX Presentations at 2016 ASCO^® Annual Meeting Reinforce Genomic Health’s Leadership in Optimising Breast Cancer Treatment

31 May 2016
Innovative Oncotype DX Test Available in Centres Throughout West of Scotland Cancer Network to Guide Treatment Decisions for Early Breast Cancer Patients

11 March 2016
Five-year Outcomes Results from European ‘PlanB’ Study Show That Breast Cancer Patients with Low Oncotype DX Recurrence Score^® Results Can be Spared Chemotherapy Despite Having High-risk Disease by Traditional Measures

Media Coverage

9 October 2016
Women Diagnosed with Breast Cancer After 70 Twice as Likely to Die from It

Press Releases

14 December 2015
Major New Study Data Demonstrates That the Oncotype DX Test Accurately Predicts Clinical Breast Cancer Outcomes, Bringing the Total Number of Patients in Prospective Outcome Studies to 50,000.

28 September 2015
Large TAILORx Outcomes Study Demonstrates 99% of Patients with Low Oncotype DX Recurrence Score Results Were Breast Cancer Relapse-free Following Five Years of Hormone Therapy Alone.

5 February 2015
As of April 1, 2015, the Oncotype DX Test Will be Available, Through an Access Scheme, as an Option to Help NHS Clinicians in England Decide Whether to Prescribe Chemotherapy in People with Early Breast Cancer.

Media Coverage

5 February 2015
Breast Cancer Test to Spare Thousands from Chemotherapy: Pioneering Treatment to Be Available on the NHS from April